ArticleJAMA oncology2022
All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane.
Article in JAMA oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Method-Comparison Validation of a Novel Capillary Blood Collection Kit, True DosePharmaceuticals (Basel, Switzerland) · 2026Article
- Development and evaluation of a novel capillary blood collection method for decentralized therapeutic drug monitoring using the True Dose kit.Scientific reports · 2025Article
- Feasibility and outcome of genomics-guided treatment selection in advanced cancer - the MEGALiT explorative clinical trial.Acta oncologica (Stockholm, Sweden) · 2025Article
- Project Confirm: Accelerated Drug Approvals for CML-Letter.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Project Confirm: Accelerated Drug Approvals for CML-Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Metronomic chemotherapy in cancer treatment: new wine in an old bottle.Theranostics · 2024Review
- Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.British journal of cancer · 2023Review
- The earlier the better? Or better late than never? Dose optimization in oncology.Journal of the National Cancer Institute · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.